复发性自发性细菌性腹膜炎二级预防:更换一线药物与不更换的结局比较
结果显示更换组SBP复发率更低(52% vs 100%),6个月死亡率更低(24% vs 57.1%,P=0.015),后续入住ICU比例更低(12% vs 46.4%,P=0.008)。
要点
- 复发性SBP患者更换预防药物后SBP复发率52%,不更换组为100%。
- 更换组6个月死亡率为24%,显著低于不更换组的57.1%(P=0.015)。
- 更换组后续入住ICU比例为12%,不更换组为46.4%(P=0.008)。
核心结论
- 复发性SBP患者在一线预防失败后更换预防药物,与更低的SBP复发率和显著更低的6个月死亡率相关。
研究设计与样本
- 患者分为两组:25例在SBP复发后更换原预防药物,28例继续使用同一药物。
主要发现
- 更换组SBP复发率为52%,不更换组为100%。
- 更换组6个月死亡率为24%,不更换组为57.1%(P=0.015)。
- 两组在其他SBP并发症发生率上无显著差异。
临床怎么用
- 对于一线药物预防失败的复发性SBP患者,临床可考虑更换预防药物以降低复发和死亡风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The American Association for the Study of Liver Diseases guidelines recommend ciprofloxacin as a first-line option for spontaneous bacterial peritonitis (SBP) prophylaxis, citing literature that is over 30 years old. There is insufficient data and guidance for prophylaxis in cases of fluoroquinolone treatment failure or intolerance. This study aimed to evaluate outcomes in patients whose antimicrobial prophylaxis was switched from first-line therapies to an alternative agent versus those who were not switched following recurrent SBP. METHODS: This study was an institutional review board-approved retrospective chart review of patients admitted to University of Kentucky HealthCare from 2014 through 2020. Patients included were 18 years of age or older with a diagnosis of recurrent SBP. The primary outcome examined was SBP recurrence rate following initial prophylaxis failure. Additional analyses targeted secondary outcomes, including 6-month mortality, development of SBP complications, development of an adverse drug reaction, and development of multidrug-resistant pathogens. RESULTS: Fifty-three patients were identified with recurrent SBP and divided into 2 cohorts: 25 patients were switched from their original prophylactic agent while 28 patients continued on the same agent after SBP recurrence. Patients in the switch group had lower rates of recurrence (52% vs 100%). Additionally, these patients had lower 6-month mortality rates (24% vs 57.1%; P = 0.015). Thirteen patients in the no-switch group and 3 patients in the switch group required intensive care on a subsequent admission (46.4% vs 12%; P = 0.008). There were no significant differences between the groups in rates of other SBP complications. CONCLUSION: Patients switched from their original prophylactic agent had lower rates of SBP recurrence with significantly lower 6-month mortality rates.
引用
- Collette K, Bethea A, Schadler A, et al. Outcomes in patients with spontaneous bacterial peritonitis utilizing first-line or alternative agents for secondary prophylaxis. Am J Health Syst Pharm. 2023. PMID: 36680798. doi:10.1093/ajhp/zxad006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。